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Introduction: Cancer is defined as the abnormal cell growth. It has always been a 
great health problem all over the world despite growing advances in its prevention 
and treatment strategies, which can cause life-threatening malignancies with high 
financial costs for patients as well as the health care system. Mounting evidence 
suggested that curcumin is potentially able to act as chemo-preventive and 
chemotherapeutic agent in different types of cancer. Nanotechnology has shown 
promising effects in the treatment of cancer. Nanoformulation provides improvements 
in bioavailability, biodistribution, specificity, and pharmacokinetics of drugs 
delivered to the site of tumor. The aim of current study is to comprehensively review 
the pharmacological effects and molecular mechanisms of nanoformulated curcumin 
and its derivatives as adjunctive therapy in preventing and treating malignancies. 
 
Methods and Results: Electronic databases including “Scopus”, “PubMed”, and 
“ScienceDirect” were searched with the keywords “cancer” in title/abstract, along 
with “curcumin” and “nanoformulation” in the whole text. Data were collected from 
the inception date until June 2017. Articles that had assessed nanoformulations of 
curcumin derivatives in an in vitro or in vivo model of cancer were selected for this 
study, and conventional formulations without using a nanonization technique were 
excluded. Various curumin nanoformulations have been prepared as anticancer agents 
including PLGA nanoparticles, cyclodextrin/cellulose nanocrystals, folate-modified 
PLA-PEG micelles, dendrosomal nanoparticles and lipid–polymer hybrid 
nanoparticles. Curcumin nanoformulations perform their anticancer activity via 
several cellular mechanisms, including induction of cell cycle arrest at different 
phases of cancer cell cycle, activation of caspase enzymes, reduction of tumor 
vascularization, reducing tumor cell invasion and metastasis, induction of 
mitochondrial damage, as well as apoptosis in the neoplasm.  
Conclusions: Nanoformulations of curcumin, result in better bioefficacy for the 
prevention and treatment of cancer. The most important improvement in 
nanoformulated curcuminoids, in comparison to their free molecules, is their better 
antineoplastic function and improved bioavailability that can result in production of 
natural anticancer agents with passive targeting of cancerous cells. However, a long 
path lies ahead of commercializing these agents, including assessment of their safety 
and efficacy in healthy as well as cancerous subjects in clinical settings. 
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